The Cline Medical Centre in Nanaimo is the Eighth Authorized PoNS Treatment™ Clinic in Canada.
NEWTOWN, Pa., Feb. 07, 2020 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq: HSDT) (TSX:HSM) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, announces the authorization of their eighth PoNS Treatment™ center in Nanaimo, British Columbia (BC), The addition of the Clinic Medical Centre (“CMC”) in Nanaimo further increases access to PoNS Treatment across Canada. Cline Medical Centre is a leading integrative and functional medicine healthcare facility located at 2090 Skaha Drive, Nanaimo, BC.
“This will be the most important thing I do in my career,” said Dr. John Cline, MD, Medical Director of Cline Medical Centre. “Cline Medical Centre is excited to announce the introduction of PoNS Treatment to our community. CMC will be the second clinic in BC to make this available to those patients suffering from mild-to-moderate traumatic brain injury.”
“With the addition of Dr. Cline’s clinic on Vancouver Island in BC, we continue to broaden patient access to the PoNS Treatment in Canada as it will be more convenient for patients suffering from mild-to-moderate traumatic brain injury to get local more direct access” said Philippe Deschamps, Chief Executive Officer of Helius.
Cline Medical Centre joins Neurotherapy Montreal in Montreal, Quebec; Surrey Neuroplastic Clinic in Surrey, BC; Advantage 4 Athletes Training Centre and Therapy Clinic in Markham, Ontario; Synaptic Spinal Cord Injury and Neuro Rehabilitation Centre in Calgary, Alberta; Apollo South Physical Therapy Centre in Ottawa, Ontario; P3 Health Clinic in Toronto, Ontario; and Clinique Cortex (a satellite clinic) in Quebec City, Quebec, as the latest Authorized PoNS Treatment Clinic in Canada.
“Mild-to-moderate traumatic brain injuries impact the lives of millions of Canadians on a daily basis. We are continuing our search to identify and recruit accomplished clinics to deploy our PoNS™ technology. We look forward to expanding our clinic authorizations to serve more and more Canadians in the near future” said Deschamps.
About Helius Medical Technologies, Inc.
Helius Medical Technologies is a neurotech company focused on neurological wellness. The Company’s purpose is to develop, license and acquire unique and non-invasive platform technologies that amplify the brain’s ability to heal itself. The Company’s first commercial product is the Portable Neuromodulation Stimulator (PoNS™). For more information, visit www.heliusmedical.com.
About the PoNS™ Device and PoNS Treatment™
The Portable Neuromodulation Stimulator (PoNS™) is an authorized class II, non-implantable, medical device in Canada intended for use as a short term treatment (14 weeks) of chronic balance deficit due to mild-to-moderate traumatic brain injury (mmTBI) and is to be used in conjunction with physical therapy. The PoNS™ is an investigational medical device in the United States, the European Union (“EU”), and Australia (“AUS”), and it is currently under review for clearance from the AUS Therapeutic Goods Administration. PoNS Treatment™ is currently not commercially available in the United States, the European Union or Australia.
About Cline Medical Centre
Cline Medical Centre is a leading integrative and functional medicine healthcare facility located on the East Coast of Vancouver Island in Nanaimo, British Columbia. Founded by Dr. John Cline, MD, in 1996, Cline Medical Centre treats a wide scope of health conditions using systematic approaches to discover the cause of body imbalances. For more information, visit http://www.clinemedical.com.
Investor Relations Contact:
Westwicke Partners on behalf of Helius Medical Technologies, Inc.
Mike Piccinino, CFA
443-213-0500
investorrelations@heliusmedical.com
Cautionary Disclaimer Statement:
Certain statements in this news release are not based on historical facts and constitute forward-looking statements or forward-looking information within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and Canadian securities laws. All statements other than statements of historical fact included in this news release are forward-looking statements that involve risks and uncertainties. Forward-looking statements are often identified by terms such as “believe,” “continue,” “look forward,” “will” and similar expressions. Such forward-looking statements include, among others, statements regarding the Company’s future clinical and regulatory development plans for the PoNS device and the potential regulatory clearance of the PoNS device.
There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those expressed or implied by such statements. Important factors that could cause actual results to differ materially from the Company’s expectations include the uncertainties associated with the regulation of commercially available medical devices in Canada, including Health Canada’s ongoing assessment of post-market data, the clinical development, regulatory submission and approval process in the United States, the European Union and Australia, as well as the Company’s capital requirements needed to achieve its business objectives and other risks detailed from time to time in the filings made by the Company with securities regulators, and including the risks and uncertainties about the Company’s business described in the “Risk Factors” sections of the Company’s Annual Report on Form 10-K for the year ended December 31, 2018, its Quarterly Report on Form 10-Q for the quarter ended September 30, 2019 and its other filings with the United States Securities and Exchange Commission and the Canadian securities regulators, which can be obtained from either at www.sec.gov or www.sedar.com.
The reader is cautioned not to place undue reliance on any forward-looking statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company assumes no obligation to update any forward-looking statement or to update the reasons why actual results could differ from such statements except to the extent required by law.
The Toronto Stock Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of the content of this news release.